Dyne Therapeutics announced the pricing of an upsized public offering of 18.3 million common shares at $20.50 each, raising approximately $375 million before expenses. The offering is expected to close around July 23, 2026, with underwriters having a 30-day option to buy additional shares. Proceeds will support Dyne's clinical programs targeting neuromuscular diseases like Duchenne muscular dystrophy. This capital raise aims to advance their therapeutic developments and clinical trials.
Tec-Do Technology Co., Limited unveiled Navos Pro at its 2026 Technology Growth Conference in Guangzhou, introducing it as the industry's first professional AI agent designed to enhance work outcomes. Navos Pro targets cross-border e-commerce, intern...
Tec-Do unveiled Navos Pro at the Technology Growth Conference 2026 in Guangzhou, presenting it as a results-driven AI solution for work focused on business growth. Navos Pro integrates professionalism, proactivity, and profitability to support cross-...
Tec-Do unveiled Navos Pro at the Technology Growth Conference 2026 in Guangzhou, an AI platform aimed at enhancing business outcomes through professional, proactive, and profitable features. The tool supports international e-commerce, marketing, and ...
Tec-Do unveiled Navos Pro at the Technology Growth Conference 2026 in Guangzhou, introducing an AI solution designed to drive measurable business outcomes in marketing, coding, and management. Navos Pro combines professional expertise, proactive oppo...
Tec-Do unveiled Navos Pro at the Technology Growth Conference 2026 in Guangzhou, positioning it as the first 'Pro-Agent' AI designed for results-driven workplace applications. Navos Pro focuses on professional, proactive, and profitable AI use, targe...
